Skip to main content
. Author manuscript; available in PMC: 2023 Apr 11.
Published in final edited form as: Cancer Immunol Res. 2021 Aug 3;9(10):1214–1228. doi: 10.1158/2326-6066.CIR-21-0265

Figure 2.

Figure 2.

minP1, a minimized immunostimulatory peptide derived from the HMGN1 NBD, retains its antitumor effects. A, The amino acid sequence of murine HMGN1 (mH) and its NBD (peptide 1, P1) and CHUD (peptide 2, P2). B, Tumor growth for mice treated with mH, P1, or P2 in combination with anti–PD-L1 treatment in each mouse from day 0 to day 24. C, The amino acid sequence of the human HMGN1 (hH) NBD and derived peptides with various lengths. D, Tumor growth after treatment with HMGN1 NBD-derived peptides in combination with anti–PD-L1 treatment in each mouse. E, Tumor growth after treatment with the minP1 (human HMGN1 NBD-derived immunostimulatory peptide) in combination with anti–PD-L1 treatment in both Colon26 and LLC models from day 0 to day 24, and tumor volume at day 24. F, Tumor rechallenge. One week after tumor clearance, mice that cleared Colon26 or LLC tumors were rechallenged with 4T1 and Colon26 tumor cells or with EO771 and LLC tumor cells, respectively. Tumor growth is representative of three independent experiments with at least eight mice/group. Data are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 using Dunnett post hoc test (compared with control); #, P < 0.05; ##, P < 0.01; ###, P < 0.001 using Student t test (comparing minP1/anti–PD-L1–treated and anti–PD-L1–treated groups). Ct, control.